Previously, USP5 was reported to exert oncogenic effects on various types of tumors, particularly breast cancer and non‐small cell lung cancer.[26] Our research elucidated the role of USP5 in conferring resistance to ripretinib in GIST. Here, USP5 is linked to breast carcinoma.